Literature DB >> 25583413

[(68)Ga-PSMA as a new tracer for evaluation of prostate cancer: comparison between PET-CT and PET-MRI in biochemical recurrence].

M Avanesov1, M Karul, T Derlin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25583413     DOI： 10.1007/s00117-014-2792-6

Source DB:  PubMed          Journal:  Radiologe        ISSN： 0033-832X            Impact factor:   0.635


× No keyword cloud information.
  10 in total

1.  68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging.

Authors:  Matthias Eder; Martin Schäfer; Ulrike Bauder-Wüst; William-Edmund Hull; Carmen Wängler; Walter Mier; Uwe Haberkorn; Michael Eisenhut
Journal:  Bioconjug Chem       Date:  2012-03-13       Impact factor: 4.774

2.  Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience.

Authors:  A Afshar-Oromieh; U Haberkorn; H P Schlemmer; M Fenchel; M Eder; M Eisenhut; B A Hadaschik; A Kopp-Schneider; M Röthke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-12-19       Impact factor: 9.236

3.  123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy.

Authors:  Shawn M Hillier; Ashley M Kern; Kevin P Maresca; John C Marquis; William C Eckelman; John L Joyal; John W Babich
Journal:  J Nucl Med       Date:  2011-06-16       Impact factor: 10.057

4.  Natural history of progression after PSA elevation following radical prostatectomy.

Authors:  C R Pound; A W Partin; M A Eisenberger; D W Chan; J D Pearson; P C Walsh
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

Review 5.  Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer.

Authors:  Arundhati Ghosh; Warren D W Heston
Journal:  J Cell Biochem       Date:  2004-02-15       Impact factor: 4.429

6.  99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.

Authors:  Shawn M Hillier; Kevin P Maresca; Genliang Lu; Ross D Merkin; John C Marquis; Craig N Zimmerman; William C Eckelman; John L Joyal; John W Babich
Journal:  J Nucl Med       Date:  2013-06-03       Impact factor: 10.057

7.  Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy.

Authors:  Satyajit Kosuri; Naveed H Akhtar; Michael Smith; Joseph R Osborne; Scott T Tagawa
Journal:  Adv Urol       Date:  2012-05-28

8.  [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients.

Authors:  Marino Cimitan; Roberto Bortolus; Sandro Morassut; Vincenzo Canzonieri; Antonio Garbeglio; Tanja Baresic; Eugenio Borsatti; Annalisa Drigo; Mauro G Trovò
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-25       Impact factor: 10.057

9.  Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.

Authors:  Ali Afshar-Oromieh; Christian M Zechmann; Anna Malcher; Matthias Eder; Michael Eisenhut; Heinz G Linhart; Tim Holland-Letz; Boris A Hadaschik; Frederik L Giesel; Jürgen Debus; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-09-27       Impact factor: 9.236

10.  Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted (99m)Tc-radioimaging agents.

Authors:  Sumith A Kularatne; Zhigang Zhou; Jun Yang; Carol B Post; Philip S Low
Journal:  Mol Pharm       Date:  2009 May-Jun       Impact factor: 5.364
  10 in total
  3 in total

1.  Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand.

Authors:  Stefano Boschi; Jason T Lee; Seval Beykan; Roger Slavik; Liu Wei; Claudio Spick; Uta Eberlein; Andreas K Buck; Filippo Lodi; Gianfranco Cicoria; Johannes Czernin; Michael Lassmann; Stefano Fanti; Ken Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-22       Impact factor: 9.236

2.  Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.

Authors:  Oluwaseun A Odewole; Funmilayo I Tade; Peter T Nieh; Bital Savir-Baruch; Ashesh B Jani; Viraj A Master; Peter J Rossi; Raghuveer K Halkar; Adeboye O Osunkoya; Oladunni Akin-Akintayo; Chao Zhang; Zhengjia Chen; Mark M Goodman; David M Schuster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04-18       Impact factor: 9.236

3.  Initial Clinical Experience with 68Ga-DOTA-NOC Prepared Using 68Ga from Nanoceria-polyacrylonitrile Composite Sorbent-based 68Ge/68Ga Generator and Freeze-dried DOTA-NOC Kits.

Authors:  Piyush Chandra; Bhakti Shetye; Rubel Chakravarty; Archana Mukherjee; Usha Pandey; Ashish Kumar Jha; Nilendu Purandare; Sneha Shah; Archi Agrawal; Ramu Ram; Ashutosh Dash; Venkatesh Rangarajan
Journal:  World J Nucl Med       Date:  2017 Apr-Jun
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.